Quantcast
Last updated on April 16, 2014 at 7:25 EDT

Latest Antiarrhythmic agents Stories

2014-02-13 08:30:36

NASDAQ: CRME TSX: COM VANCOUVER, Feb. 13, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that a poster titled "Medical conversion with Vernakalant on postoperative cardio-surgical patients" by Thöne, M. et al., from the Department of Cardiovascular Surgery at the Heinrich-Heine-University Düsseldorf located in Düsseldorf, Germany, was presented at the 43(rd) Annual Meeting of the Germany Society for Thoracic and Cardiovascular Surgery...

2014-02-07 08:24:20

CARY, N.C., Feb. 7, 2014 /PRNewswire/ -- Covis Pharmaceuticals today announced that LANOXIN® is now offered in four dosage strengths, including the new 0.0625mg and 0.1875mg strengths, for the treatment of mild-to-moderate heart failure in adults, and for the control of ventricular response rate in adult patients with chronic atrial fibrillation. Current dosing options of 0.250mg and 0.125mg are still available. These four convenient strengths are currently stocked in all major...

2014-01-16 16:23:43

WOODCLIFF LAKE, N.J., Jan. 16, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.a.r.l. to distribute the authorized generic version of Covis's Lanoxin(®) (digoxin) Tablets. The Lanoxin(®) brand has been relied upon for its quality and availability for more than 50 years. Digoxin tablets are indicated for treatment of mild to moderate heart failure in adults;...

2013-11-19 12:30:10

- Once-daily edoxaban, evaluated in two treatment arms (60 mg and 30 mg), achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism DALLAS and TOKYO, Nov. 19, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results today from the phase 3 ENGAGE AF-TIMI 48 study.(1) This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met...

2013-11-12 08:35:17

CLEVELAND, Nov. 12, 2013 /PRNewswire/ -- ChanRx, a firm developing medicines for cardiovascular diseases, today announced that it will be presenting the results of its Phase IIb study of vanoxerine (GBR-12909), a drug under study for the treatment of atrial fibrillation, at the American Heart Association 2013 Scientific Sessions conference. The study, titled "COR-ART: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Modification Study to Evaluate Single Oral Doses of...

2013-10-28 12:25:16

NASDAQ: CRME TSX: COM VANCOUVER, Oct. 28, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced that the abstract, Conversion of Acute Atrial Fibrillation with Propafenone or Vernakalant, is being presented as an oral presentation by Dr. Diego Conde, Chief of Cardiovascular Emergency Care Section, Instituto Cardiovascular de Buenos Aires, at the Venice Arrhythmias meeting, being held in Venice, Italy, October 27-29, 2013. This abstract is competing...

2013-09-23 08:28:52

NASDAQ: CRME   TSX: COM VANCOUVER, Sept. 23, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced publication of positive data from an open label study in patients with atrial fibrillation that compared treatment with vernakalant intravenous (IV) to oral propafenone and oral flecainide. Patients treated with vernakalant achieved conversion to normal sinus rhythm in a median time of 12 minutes compared to 151 minutes for the propafenone group and...

2013-09-20 16:24:05

OAKLAND, Calif., Sept. 20, 2013 /PRNewswire/ -- Digoxin, a drug commonly used to treat heart conditions, was associated with a 72 percent higher rate of death among adults with newly diagnosed systolic heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Cardiovascular Quality and Outcomes. (Logo: http://photos.prnewswire.com/prnh/20130718/SF49717LOGO) Digoxin is a drug derived from digitalis, a plant that has been used for...

2013-06-26 16:41:42

PREFER AF shows European clinicians adhere well to AF guidelines Two important studies were released at the Late Breaking Clinical Trials session II at EHRA EUROPACE 2013. The PREFER AF study2 found that Oral anticoagulation is now used in over 85% of patients with atrial fibrillation (AF) eligible for therapy. And ISSUE (the International Study on Syncope of Uncertain Aetiology) determined that cardiac pacing is more effective in patients with presumed neurally mediated syncope (NMS) and...

2013-03-28 08:28:02

NASDAQ: CRME   TSX: COM VANCOUVER, March 28, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announces the addition of Steen Juul-Möller, M.D., Ph.D./DMSc., FESC to Cardiome's management team as Medical Director, Europe.  In his capacity of Medical Director, Dr. Juul-Möller will oversee Cardiome's clinical and medical affairs activities. Dr. Juul-Möller has held his clinical position at the...